Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 1,495,000 shares of common stock for an aggregate price to the public of approximately $113.62 million including 195,000 shares sold pursuant to the underwriters’ option to purchase additional shares. The shares are listed on the New York Stock Exchange under the symbol “PEN.”

Headquartered in Alameda, California, Penumbra, Inc. is a global healthcare company focused on interventional therapies. Penumbra designs, develops, manufactures and markets innovative devices and has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jason Bassetti and Donald K. Lang. Partner Rachel D. Kleinberg and associate Yoojin L. Kim provided tax advice. Associate Preeti Krishnan provided Investment Company Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post